A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
Hexarelin is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It has been investigated for its ability to stimulate growth hormone (GH) secretion through activation of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.
Hexarelin has been studied in preclinical and human research examining pituitary growth hormone secretion, neuroendocrine regulation and GH–IGF-1 axis physiology. Its biological activity involves receptor-mediated signaling that promotes endogenous growth hormone release.
Additional experimental research has investigated Hexarelin’s interactions with cardiovascular tissues and cardiac signaling pathways. These findings have generated scientific interest in biological activities beyond growth hormone secretion.
Hexarelin 10 mg is presented as an experimental research peptide for laboratory and scientific applications. The stated quantity refers to the amount of peptide contained in the product and should not be interpreted as a recommended human dosage.
Product: Hexarelin
Strength: 10 mg
Category: Growth Hormone
Compound classification: Synthetic hexapeptide; growth hormone secretagogue
Research target: Growth hormone secretagogue receptor (GHS-R1a) and associated neuroendocrine signaling pathways
Research focus: Growth hormone secretion, pituitary regulation, GH–IGF-1 axis physiology and experimental cardiovascular signaling
Mechanism: Activation of GHS-R1a-mediated signaling pathways that stimulate endogenous growth hormone secretion
Pharmacological profile: Experimental growth hormone secretagogue investigated in preclinical and human studies, with documented growth hormone-releasing activity and additional exploratory cardiovascular research
Intended use: Laboratory and research use only
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.